University of Texas Medical Branch, Galveston, TX
S. Gail Eckhardt, MD is Professor and Head of the Division of Medical Oncology at the University of Colorado Denver and Health Sciences Center where she also holds the Stapp/Harlow Endowed Chair for Cancer Research.
After graduating from the University of Texas Medical Branch in Galveston, Dr. Eckhardt completed her internship and residency at the University of Virginia Medical Center. After a post-doctoral fellowship at the Scripps Research Foundation, she completed her training in medical oncology at the University of California at San Diego.
Following fellowship, Dr. Eckhardt joined the faculty of the Cancer Therapy and Research Center, Institute for Drug Development in San Antonio, Texas, where she held the position of Associate Director of Clinical Research.In 1999, Dr. Eckhardt joined the facutly of the University of Colorado School of Medicine to set up a Phase I program. In 2004 she became the Director of the Developmental Center. Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the NCI Developmental Therapeutics Study Section. She is also a member of two NCI Steering Committees: Gastrointestinal and Investigational Drugs. In addition, Dr. Eckhardt has been an Associate Editor of Clinical Cancer Research, the Journal of Clinical Oncology, and Investigational New Drugs. Therapeutics Program in the University of Colorado Cancer Center.
Dr. Eckhardt is the Principal Investigator on three NIH grants involving early clinical trials, mentoring, and colorectal cancer research and has conducted numerous phase I and II clinical trials. She has published over 70 manuscripts and serves on numerous advisory boards. Her area of interest is in the preclinical and clinical development of combinations of molecularly targeted compounds, with a laboratory focus on colorectal cancer.
Chow LQ, Eckhardt SG Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007 Mar 1;25(7):884-96. PMID: 17327610
Medeiros BC, Landau HJ, Morrow M, Lockerbie RO, Pitts T, Eckhardt, SG, The farnesyl
transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein,
and demonstrates significant cytotoxic synergism against human leukemia cell lines.
Leukemia. 2007 Apr;21(4):739-46. Epub 2007 Feb 1. PMID: 17268526
Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG, Novel targets in solid tumors: MEK
inhibitors. Clin Adv Hematol Oncol. 2006 Nov;4(11):831-6. PMID: 17143253
U01 CA099176 - Early Clinical Trials with Phase I Emphasis
T32 CA079446-06A1 -Training in Pharmacology of Antineoplastic Agents
R21 CA101716 - Overcoming Age-Dependent Barriers to Early Phase Trials